Compare Indonesia Energy Corporation Limited (INDO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs Novo Nordisk A/S — how do they compare? Indonesia Energy Corporation Limited trades at $2.79 (market cap $43.24M), while Novo Nordisk A/S trades at $38.54 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 3823.1× Indonesia Energy Corporation Limited's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Indonesia Energy Corporation Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Indonesia Energy Corporation Limited for 24 Days and Novo Nordisk A/S for 116 Days on average.
| INDO | NVO | |
|---|---|---|
Market Cap | $43.24M | $165.31B |
Volume | 116,953 | 11,432,838 |
Sector | Energy | Health |
52-Week High | $6.74 | $63.98 |
52-Week Low | $2.49 | $35.29 |
Typical Hold Time | 24 Days | 116 Days |
Enterprise Value | $38.18M | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.77, unchanged on the day, with a bearish technical signal driven by moving averages. The company reported a net loss of $5.10 million in 2025 on revenue of $2.01 million, reflecting negative profit margins and cash flow from operations. Recent news highlights operational progress, including oil discovery at the K-29 well and participation in investment conferences.
Despite a 100% buy rating from 3 analysts, INDO faces significant financial challenges with negative profitability and cash burn. Investment potential hinges on successful execution of drilling operations to boost revenue, but risks include sustained losses, high valuation multiples relative to sales, and reliance on financing activities.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
